Syne Qua Non Limited


Veristat is a clinical research organization (CRO) committed to partnering with clients to advance therapies through the clinical development and regulatory submission process. They focus on building true partnerships based on trust, respect, understanding, and agility, supporting success in bringing therapies to market to improve and save lives.

Industries

life-science
medical
pharmaceutical

Nr. of Employees

large (251-1000)

Syne Qua Non Limited

London, England, United Kingdom, Europe


Services

End-to-end clinical development services including trial planning, conduct, biometrics, medical writing, regulatory submission support, and post-approval activities.

High-level strategic consulting for clinical development, program planning, protocol design, and regulatory strategy including adaptive designs and statistical planning.

Regulatory consulting, agency meeting support, regulatory publishing, and preparation of marketing applications for global health authorities.

Project management, monitoring, site management, and operational coordination to execute clinical studies and meet milestones.

Clinical data management, biostatistical design and analysis, statistical programming, and implementation of data standards for regulatory readiness.

Medical monitoring, clinical trial safety management, DMC facilitation, and post-marketing safety support.

View All Services

Expertise Areas

  • Clinical trial management
  • Adaptive trial design and simulation
  • Regulatory submissions and strategy
  • Regulatory intelligence and guidance monitoring
  • Show More (7)

Key Technologies

  • Adaptive clinical trial design
  • Trial simulation and modeling
  • Bayesian study design
  • Clinical data standards implementation
  • Show More (6)

News & Updates

On Saturday, February 4, Team Veristat joined the battle against rare cancers at the 2017 Cycle for Survival event in Boston, MA, raising over $25,000.

The EMA has published its third version of the guidance on managing clinical trials during the COVID-19 pandemic, recommending a risk-based approach and adaptations to trial conduct.

Veristat has celebrated over 105 regulatory approvals for various therapies.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.